Literature DB >> 24735346

Evaluation of antinuclear antibodies by indirect immunofluorescence and line immunoassay methods': four years' data from Turkey.

Asli Gamze Sener1, Ilhan Afsar, Mustafa Demirci.   

Abstract

The presence of antinuclear antibodies (ANAs), directed against intracellular antigens, is a hallmark of systemic autoimmune rheumatic diseases. The indirect immunofluorescence (IIF) assay is among the most commonly used routine methods for ANA detection as the screening test. The objective of the study was to evaluate ANA patterns in a 4-year period retrospectively. All 19 996 serum samples that were sent to the Laboratory of Medical Microbiology of the tertiary Hospital by any hospital department between 1 January 2009 and 1 January 2013 with a request to test for ANA, anti-ENA or both were included in the study. Of these samples, 4375 (21.9%) were ANA-IIF-positive and 15621 (78.1%) were ANA-IIF-negative. The presented ANA-positive samples consisted of 2392 (54.67%) homogenous, 818 (18.70%) speckled, 396 (9.05%) centromere, 242 (5.53%) nucleolar, 213 (4.87%) nuclear dots, 178 (4.07%) cytoplasmic (except for actin and golgi), 24 (0.55%) actin, 9 (0.21%) golgi, 53 (1.21%) nuclear membrane and 50 (1.14%) mixed pattern. Totally 7800 samples were examined by LIA. Of these samples, 3440 were positive and 4307 were negative with IIF and LIA. In addition, 22 samples were detected as IIF-positive but LIA-negative, whereas the rest 31 samples were IIF-negative but LIA-positive. ANA patterns in 22 IIF-positive samples were homogenous (9), speckled (5), golgi (4), cytoplasmic (3) and nucleolar (1). SSA/Ro-52, SSB/La and Scl-70 positivity were detected in 31 IIF-negative/LIA-positive samples by LIA. The present study comes forward with its overall scope, which covers 4-year data obtained in tertiary hospital located in the western part of Turkey.
© 2014 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Antinuclear antibody; immunofluorescence assay; line assay

Mesh:

Substances:

Year:  2014        PMID: 24735346     DOI: 10.1111/apm.12275

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  4 in total

Review 1.  Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others.

Authors:  Minoru Satoh; Angela Ceribelli; Tomoko Hasegawa; Shin Tanaka
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-08       Impact factor: 10.817

2.  A cell-based assay for detection of anti-fibrillarin autoantibodies with performance equivalent to immunoprecipitation.

Authors:  Gerson Dierley Keppeke; Minoru Satoh; Cristiane Kayser; Pedro Matos; Tomoko Hasegawa; Shin Tanaka; Larissa Diogenes; Rogerio Quintiliano Amaral; Silvia Helena Rodrigues; Luis Eduardo Coelho Andrade
Journal:  Front Immunol       Date:  2022-09-26       Impact factor: 8.786

3.  Antinuclear Antibody Profiling in Patients of a Tertiary Care Centre in Central India.

Authors:  Prishni Gupta; Pratishtha Agrawal; Neha Rani Verma; Seema Shah; Suprava Patel; Rachita Nanda; Eli Mohapatra
Journal:  Indian J Clin Biochem       Date:  2020-09-09

4.  Confirmation of anti-DFS70 antibodies is needed in routine clinical samples with DFS staining pattern.

Authors:  Esvet Mutlu; Mete Eyigör; Derya Mutlu; Meral Gültekin
Journal:  Cent Eur J Immunol       Date:  2016-03-24       Impact factor: 2.085

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.